Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women
Authors
Keywords
immunobridging, noninferiority, human papillomavirus, vaccine, <em class="EmphasisTypeItalic ">Escherichia coli</em>, girls
Journal
Science China-Life Sciences
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-06-24
DOI
10.1007/s11427-019-9547-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: An interim analysis of a randomized clinical trial
- (2019) You-Lin Qiao et al. JNCI-Journal of the National Cancer Institute
- Worldwide burden of cancer attributable to HPV by site, country and HPV type
- (2017) Catherine de Martel et al. INTERNATIONAL JOURNAL OF CANCER
- Characterization of an Escherichia coli -derived human papillomavirus type 16 and 18 bivalent vaccine
- (2017) Ying Gu et al. VACCINE
- Escherichia coli-derived virus-like particles in vaccine development
- (2017) Xiaofen Huang et al. npj Vaccines
- Cancer statistics in China, 2015
- (2016) Wanqing Chen et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women
- (2016) Ole-Erik Iversen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Present status of human papillomavirus vaccine development and implementation
- (2015) Rolando Herrero et al. LANCET ONCOLOGY
- A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women
- (2015) Elmar A. Joura et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunogenicity and Safety of a 9-Valent HPV Vaccine
- (2015) P. Van Damme et al. PEDIATRICS
- Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial
- (2015) Ting Wu et al. VACCINE
- Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination
- (2014) Hui Zhao et al. Human Vaccines & Immunotherapeutics
- Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women
- (2013) Simon R. M. Dobson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety of anEscherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine
- (2013) Yuemei Hu et al. Human Vaccines & Immunotherapeutics
- A multi-center survey of age of sexual debut and sexual behavior in Chinese women: Suggestions for optimal age of human papillomavirus vaccination in China
- (2012) Fang-Hui Zhao et al. Cancer Epidemiology
- Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule
- (2011) Barbara Romanowski et al. Human vaccines & immunotherapeutics
- HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine
- (2008) Elmar A. Joura et al. VACCINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started